Intensity Therapeutics appoints Thomas Dubin to Board, restores Audit Committee compliance

INTENSITY THERAPEUTICS, INC.

Thomas I. H. Dubin appointed as Class I director, expanding Board from 4 to 5 members.
Dubin will serve on Audit Committee, restoring Nasdaq compliance after Daniel Donovan's resignation.
Granted options to purchase 50,000 shares at $4.42 per share, vesting in four equal installments.
Dubin brings deep experience from Alexion Pharmaceuticals (former chief legal officer) and other biotech roles.
Four of five Board members are now independent per Nasdaq standards.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Thomas I. H. Dubin

Class I director

INTS · INTENSITY THERAPEUTICS, INC.

Effective: 2024-05-14
Filed: May 15, 2024, 7:59 PM ET

appointed Thomas I. H. Dubin to the Board as a Class I director.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Thomas I. H. Dubin was appointed as Class I director at INTENSITY THERAPEUTICS, INC..

Action: appointed
Role: Class I director

Exact text from the filing

appointed Thomas I. H. Dubin to the Board as a Class I director.

View on SEC.gov

INTENSITY THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001567264-24-000017

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.